There is already early‐stage progress with PIEZO pharmacology, particularly for PIEZO1.[166] A commonly used small molecule positive enhancer (agonist) is Yoda1, which activates PIEZO1 but not PIEZO2 channels.[166] A Yoda1‐related small molecule, Dooku1, inhibits PIEZO1 channels, and the spider toxin, GsMTx4, inhibits PIEZO1 and PIEZO2 without being selective for either.[166] The suggested vascular and vascular related diseases that could potentially be addressed by a PIEZO enhancer most commonly involve PIEZO1, as in lymphedema for example (Table 1). This evidence concerns the gene PIEZO2 and lymphedema.